Literature DB >> 23748232

[Prognostic factors for locoregional recurrence after neoadjuvant chemotherapy. Results of a combined analysis from NSABP B-18 and B-27].

D Krug1.   

Abstract

Mesh：

Year:  2013        PMID： 23748232     DOI： 10.1007/s00066-013-0350-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  10 in total

1.  Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.

Authors:  Gunter von Minckwitz; Michael Untch; Eveline Nüesch; Sibylle Loibl; Manfred Kaufmann; Sherko Kümmel; Peter A Fasching; Wolfgang Eiermann; Jens-Uwe Blohmer; Serban Dan Costa; Keyur Mehta; Jörn Hilfrich; Christian Jackisch; Bernd Gerber; Andreas du Bois; Jens Huober; Claus Hanusch; Gottfried Konecny; Werner Fett; Elmar Stickeler; Nadia Harbeck; Volkmar Müller; Peter Jüni
Journal:  Breast Cancer Res Treat       Date:  2010-11-03       Impact factor: 4.872

2.  Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation.

Authors:  Jean L Wright; Cristiane Takita; Isildinha M Reis; Wei Zhao; Kunal Saigal; Aaron Wolfson; Arnold Markoe; Mecker Moller; Judith Hurley
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

3.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

Authors:  Gunter von Minckwitz; Michael Untch; Jens-Uwe Blohmer; Serban D Costa; Holger Eidtmann; Peter A Fasching; Bernd Gerber; Wolfgang Eiermann; Jörn Hilfrich; Jens Huober; Christian Jackisch; Manfred Kaufmann; Gottfried E Konecny; Carsten Denkert; Valentina Nekljudova; Keyur Mehta; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2012-04-16       Impact factor: 44.544

4.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

5.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Authors:  José Baselga; Ian Bradbury; Holger Eidtmann; Serena Di Cosimo; Evandro de Azambuja; Claudia Aura; Henry Gómez; Phuong Dinh; Karine Fauria; Veerle Van Dooren; Gursel Aktan; Aron Goldhirsch; Tsai-Wang Chang; Zsolt Horváth; Maria Coccia-Portugal; Julien Domont; Ling-Min Tseng; Georg Kunz; Joo Hyuk Sohn; Vladimir Semiglazov; Guillermo Lerzo; Marketa Palacova; Volodymyr Probachai; Lajos Pusztai; Michael Untch; Richard D Gelber; Martine Piccart-Gebhart
Journal:  Lancet       Date:  2012-01-17       Impact factor: 79.321

6.  Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.

Authors:  Eleftherios P Mamounas; Stewart J Anderson; James J Dignam; Harry D Bear; Thomas B Julian; Charles E Geyer; Alphonse Taghian; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-10-01       Impact factor: 44.544

7.  Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.

Authors:  Eugene H Huang; Susan L Tucker; Eric A Strom; Marsha D McNeese; Henry M Kuerer; Aman U Buzdar; Vicente Valero; George H Perkins; Naomi R Schechter; Kelly K Hunt; Aysegul A Sahin; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2004-12-01       Impact factor: 44.544

8.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

Authors:  B Fisher; J Bryant; N Wolmark; E Mamounas; A Brown; E R Fisher; D L Wickerham; M Begovic; A DeCillis; A Robidoux; R G Margolese; A B Cruz; J L Hoehn; A W Lees; N V Dimitrov; H D Bear
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

9.  Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy.

Authors:  Sean E McGuire; Ana M Gonzalez-Angulo; Eugene H Huang; Susan L Tucker; Shu-Wan C Kau; Tse-Kuan Yu; Eric A Strom; Julia L Oh; Wendy A Woodward; Welela Tereffe; Kelly K Hunt; Henry M Kuerer; Aysegul A Sahin; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-06       Impact factor: 7.038

Review 10.  Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer.

Authors:  Barbara L Fowble; John P Einck; Danny N Kim; Susan McCloskey; Jyoti Mayadev; Catheryn Yashar; Steven L Chen; E Shelley Hwang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-06-01       Impact factor: 7.038
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.